Introduction to Module 7 Case Study
Exploring Module 7 Case Study reveals several interesting facts. Dr. Kamau Pierre, with the Translational Disease Modeling Group at Sanofi, discusses how Quantitaive Systems Pharmacology ...
Module 7 Case Study Comprehensive Overview
Dr. Binfeng Xia with Sanofi U.S. shows how Physiologically Based Pharmokinetic (PBPK) models were used to support Eliglustat ... Dr. Pascal Chanu talks about how MIDD is used to optimize a pediatric program. The drug discussed is CERA, which stands for ... This
Module 7 Case Study 2
Summary & Highlights for Module 7 Case Study
- Professor Jason E. Farley, Associate Professor and Director of The REACH Initiative of The Johns Hopkins School of Nursing, ...
- Dr. Hoai-Thu Thai with Sanofi explains how MIDD was used to support isatuximab (Sarclisa) dosing regimen selection in ...
- Dr. Dinko Rekic of Astra-Zeneca shows how the FDA MIDD Pilot Program enabled a Phase 2 trial start prior to multiple standing ...
- Dr. Maria Laura Sargentini-Maier with Sanofi discusses how MIDD was used to support dosing recommendations of ...
- Module 7 - Reliability Testing in SPSS (Case Study Intro)
Stay tuned for more updates related to Module 7 Case Study.
